VIRIDIAN THERAPEUTICS INC's ticker is VRDN and the CUSIP is 92790C104. A total of 126 filers reported holding VIRIDIAN THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.13 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $4,799,680 | -16.4% | 201,752 | -59.3% | 5.81% | +11.1% |
| Q2 2022 | $5,739,000 | -37.4% | 496,012 | 0.0% | 5.23% | -23.1% |
| Q1 2022 | $9,171,000 | -23.3% | 496,012 | -18.0% | 6.80% | +62.7% |
| Q4 2021 | $11,956,000 | -19.7% | 604,774 | -33.2% | 4.18% | -4.5% |
| Q3 2021 | $14,887,000 | -5.3% | 904,978 | +5.2% | 4.38% | +12.0% |
| Q2 2021 | $15,728,000 | +38.3% | 859,910 | +26.3% | 3.91% | +79.1% |
| Q1 2021 | $11,376,000 | – | 680,768 | – | 2.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 2,699,865 | $78,863,057 | 13.28% |
| COMMODORE CAPITAL LP | 2,020,166 | $59,009 | 8.89% |
| ACUTA CAPITAL PARTNERS, LLC | 396,500 | $11,581,765 | 7.13% |
| Fairmount Funds Management LLC | 1,369,623 | $40,006,688 | 6.35% |
| Paradigm Biocapital Advisors LP | 1,751,167 | $51,151,588 | 6.00% |
| Vivo Capital, LLC | 1,678,207 | $49,020 | 5.64% |
| TCG Crossover Management, LLC | 983,610 | $28,731,248 | 5.07% |
| Kynam Capital Management, LP | 1,034,697 | $30,223,499 | 4.64% |
| Octagon Capital Advisors LP | 824,200 | $24,074,882 | 3.75% |
| Logos Global Management LP | 1,000,000 | $29,210,000 | 3.42% |